Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Long-course Chemoradiotherapy Followed by PD-1 Monoclonal Antibody for Locally Advanced Mid-low Rectal Cancer

NCT06493240 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT06493240
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06493240 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Long-course Chemoradiotherapy Followed by PD-1 Monoclonal Antibody for Locally Advanced Mid-low Rectal Cancer
Lead sponsor
Peking University People's Hospital
Phase
Phase 2
Overall status
Completed
Start date
January 1, 2023
Completion date
April 1, 2025
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced rectal cancer